| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-06 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.23 | 3e-05 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.2 | 6e-05 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.15 | 9e-05 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.19 | 0.0001 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0004 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0007 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0007 |